Cellular Therapies Overview

Principles

Definition

Cellular therapies is a medical treatment methodology involving the introduction of viable cells or cellular material into a patient to achieve a medicinal effect, such as fighting diseases or regenerating damaged tissues. This approach utilizes living cells as the therapeutic agent, often involving their modification or selection to restore compromised biological functions.

Ontological type

Clinical Applications

Core Modalities

Manufacturing and Processing

Key developments

Key Figures

Hematopoietic Stem Cell Paradigm era

Irving L. Weissman[1] of Massachusetts Institute of Technology[3] and University of California, San Francisco[4] was a central figure in the Hematopoietic Stem Cell Paradigm era. His key contribution was the Purification and Characterization of Mouse Hematopoietic Stem Cells[7], a landmark study that established purification as a benchmark for stem-cell frequency and potency and underpinned marrow and cord-blood grafting. Gerald J. Spangrude[2] of Stanford University[5] and University of Utah[6] was another pivotal figure in the Hematopoietic Stem Cell Paradigm era. He co-authored Purification and Characterization of Mouse Hematopoietic Stem Cells[7], a study that helped establish purification strategies and benchmarks for HSC frequency and potency, enabling multi-lineage reconstitution crucial to this era.

MSC Immunomodulatory Paradigm era

Katarina Le Blanc [1] is a central figure in the MSC immunomodulatory paradigm during this era, with affiliations at Karolinska Institutet [3] and Boston University [4]. Le Blanc [1] co-authored the International Society for Cellular Therapy's Minimal criteria for defining multipotent mesenchymal stromal cells [6], helped advance third-party haploidentical MSC therapy for severe acute graft-versus-host disease [7], and documented limited long-term engraftment in humans [8], collectively shaping the era's emphasis on immunomodulation and paracrine effects. Darwin J. Prockop [2] is a central figure in this era, with affiliations at University of Pennsylvania [5] and Karolinska Institutet [3]. Prockop [2] contributed to foundational MSC biology and translational work, including the Minimal criteria paper [6] and the transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta [9], which anchored the shift toward immunomodulatory, paracrine roles over durable engraftment.

Allogeneic Engineered Immune Cells era

Sundar Jagannath [1] is associated with the University of California, San Francisco [3] and Johns Hopkins University [4] in this era of allogeneic engineered immune cells. His key contributions include the CARTITUDE-1 [7] study, a phase 1b/2 open-label investigation of a BCMA-directed CAR-T therapy, which demonstrated meaningful clinical activity and underscored the role of receptor design and safety features in advancing cellular therapies. Nikhil C. Munshi [2] is affiliated with Harvard University [5] and the University of Washington [6] in this era. His key contributions include co-authoring the CARTITUDE-1 [7] paper and advancing translational and safety frameworks for BCMA-targeted CAR-T therapies, informing scalable design and allogeneic deployment strategies.